Article type
Year
Abstract
Objectives: The aim of this presentation is to discuss the relevance of the Cochrane Physical and Rehabilitation Medicine (PRM) Field that is now under development.
What is PRM: PRM is “an independent medical specialty concerned with the promotion of physical and cognitive functioning, activities (including behaviour), participation (including quality of life) and modifying personal and environmental factors” in all ages and health conditions (European Union of Medical Specialists (UEMS)). PRM is recognized by the World Health Organization (WHO), and part of the UEMS.
PRM and Cochrane now: All physicians should deal with prevention, diagnosis, treatment and rehabilitation. Rehabilitation is a general health strategy that aims to enable people experiencing disability to achieve and maintain optimal functioning. So, PRM is cross-sectional to all medical activities, mainly neurological and musculoskeletal, but also cardiovascular, respiratory, urogynecological, etc. Since Cochrane is organized in Groups, based on diseases and/or body areas (e.g. Stroke, Back, Musculoskeletal, etc.), the 242 reviews of PRM interest are dispersed among different Groups (Table 1).
Interest from PRM to develop Cochrane PRM: The European Society of PRM (ESPRM) started an Evidence Based Medicine (EBM) Committee to strengthen the EBM approach in PRM. The aims are to develop a strict collaboration with Cochrane to systematically collect and spread PRM Cochrane Reviews, produce PRM 'umbrella reviews', study specific methodological issues of PRM research and increase visibility of EBM activities relevant to PRM.
Interest from Cochrane to develop Cochrane PRM: PRM focuses on disability, functioning and chronicity: hence, the attention on these increasingly important health conditions will improve PRM. PRM research has specific methodological issues (complex treatments, difficulty with RCTs). Cochrane PRM will challenge and help the relevant Method Groups.
Conclusions: An exploratory meeting will be held at Brescia University (Italy) in September 2016 and submission for approval of Cochrane PRM will be submitted to the Steering Group before the Seoul Colloquium.
What is PRM: PRM is “an independent medical specialty concerned with the promotion of physical and cognitive functioning, activities (including behaviour), participation (including quality of life) and modifying personal and environmental factors” in all ages and health conditions (European Union of Medical Specialists (UEMS)). PRM is recognized by the World Health Organization (WHO), and part of the UEMS.
PRM and Cochrane now: All physicians should deal with prevention, diagnosis, treatment and rehabilitation. Rehabilitation is a general health strategy that aims to enable people experiencing disability to achieve and maintain optimal functioning. So, PRM is cross-sectional to all medical activities, mainly neurological and musculoskeletal, but also cardiovascular, respiratory, urogynecological, etc. Since Cochrane is organized in Groups, based on diseases and/or body areas (e.g. Stroke, Back, Musculoskeletal, etc.), the 242 reviews of PRM interest are dispersed among different Groups (Table 1).
Interest from PRM to develop Cochrane PRM: The European Society of PRM (ESPRM) started an Evidence Based Medicine (EBM) Committee to strengthen the EBM approach in PRM. The aims are to develop a strict collaboration with Cochrane to systematically collect and spread PRM Cochrane Reviews, produce PRM 'umbrella reviews', study specific methodological issues of PRM research and increase visibility of EBM activities relevant to PRM.
Interest from Cochrane to develop Cochrane PRM: PRM focuses on disability, functioning and chronicity: hence, the attention on these increasingly important health conditions will improve PRM. PRM research has specific methodological issues (complex treatments, difficulty with RCTs). Cochrane PRM will challenge and help the relevant Method Groups.
Conclusions: An exploratory meeting will be held at Brescia University (Italy) in September 2016 and submission for approval of Cochrane PRM will be submitted to the Steering Group before the Seoul Colloquium.